SCHEMBL6857750

SCHEMBL6857750

COC(=O)[C@@H]1C[C@@H](Oc2nc(-c3ccc(C)cc3)nc3c2oc2ccccc23)CN1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
MAPT P10636 8/20 0.41
TSHR P16473 3/20 0.41
KDM4E B2RXH2 3/20 0.41
HPGD P15428 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 5/20 0.40
KMT2A Q03164 5/20 0.40
POLB P06746 2/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
PIM1 P11309 1/20 0.39
MEN1 O00255 4/20 0.39
GAA P10253 2/20 0.39
CHEK2 O96017 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20305914 0.94 ALDH1A1 (0.46) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL6858211 0.90 ALDH1A1 (0.38) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL6857748 0.78 MCL1 (0.39) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL17805650 0.77 PIM1 (0.46) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL15305648 0.77 CHEK2 (0.45) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL12033660 0.77 CHEK2 (0.45) ALDH1A1MAPTTSHRKDM4EHSD17B10
SCHEMBL7806744 0.73 SSTR4 (0.43) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL1536578 0.73 SSTR4 (0.43) ALDH1A1MAPTTSHRKDM4EHPGD
SCHEMBL12774499 0.73 SSTR4 (0.43) ALDH1A1MAPTTSHRKDM4EHPGD
Hydrochloric Acid SCHEMBL1536577 0.72 SSTR4 (0.42) ALDH1A1MAPTTSHRKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389560-B2 HCV protease inhibitors TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2013-03-05 US disclosed
US-20110065737-A1 HCV PROTEASE INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065737-A1 HCV PROTEASE INHIBITORS RNASE1, HAVCR2, CTRL ALDH1A1 814/4885MAPT 3434/4885TSHR 3322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.